Evaluating the Frequency of Mole Checks by a Dermatologist and Correlated Variables in a Global Survey across 17 Countries: HELIOS Project
- PMID: 39177162
- PMCID: PMC11358839
- DOI: 10.2340/actadv.v104.40929
Evaluating the Frequency of Mole Checks by a Dermatologist and Correlated Variables in a Global Survey across 17 Countries: HELIOS Project
Abstract
Secondary prevention of skin cancer consists in early detection of malignant lesions through patients' mole self-examination and medical examination. The objective of this study was to assess the self-reported frequency of mole examination in a large, representative sample of the adult general population of 17 countries from all continents. Of a total of 17,001 participants, 4.8% had their moles checked by a dermatologist more than once a year, 11.3% once a year, 8.4% every 2-3 years, 12.4% once in a while, 10.3% once in lifetime, and 52.6% of participants had never performed a mole examination. Egypt was the country with the highest prevalence of people who performed a moles check more than once a year (15.9%), followed by Brazil and the USA. A higher frequency of mole checks was associated with sex (man vs woman), higher education, higher income, fair phototype, history of skin cancer, medical insurance, and sun-protective behaviours. Despite recommendations by health providers, it appears that the frequency of mole checks in the general population is still low. It is necessary for dermatologists to keep informing at-risk populations about the importance of moles check, with particular care regarding categories that less frequently adhere to secondary prevention measures.
Conflict of interest statement
HWL is an investigator for L’Oréal, has served as a consultant for La Roche-Posay, and has been a speaker on a general educational session for La Roche-Posay. TP reports personal fees from La Roche Posay during the conduct of the study and personal fees from L’Oréal. CLG reports receiving honorarium from La Roche-Posay, Galderma, and Cantabria Lab. HYK reports personal fees from L’Oréal during the conduct of the study. AM reports personal fees from L’Oréal during the conduct of the study. JO-C reports personal fees from La Roche Posay during the conduct of the study. SP reports personal fees from La Roche Posay during the conduct of the study and personal fees and non-financial support from La Roche Posay. SS has served as a consultant for La Roche Posay and has participated as a speaker in an educational session for La Roche-Posay. LW reports personal fees from La Roche Posay during the conduct of the study. ALD, CLF, and DK are employees of La Roche Posay. JK reports personal fees from La Roche Posay during the conduct of the study and grants and personal fees from L’Oréal. FL and BD have nothing to disclose.
Similar articles
-
Screening for reducing morbidity and mortality in malignant melanoma.Cochrane Database Syst Rev. 2019 Jun 3;6(6):CD012352. doi: 10.1002/14651858.CD012352.pub2. Cochrane Database Syst Rev. 2019. PMID: 31157404 Free PMC article.
-
Self screening for risk of melanoma: validity of self mole counting by patients in a single general practice.BMJ. 1995 Apr 8;310(6984):912-6. doi: 10.1136/bmj.310.6984.912. BMJ. 1995. PMID: 7719184 Free PMC article.
-
Factors in Early Adolescence Associated With a Mole-Prone Phenotype in Late Adolescence.JAMA Dermatol. 2017 Oct 1;153(10):990-998. doi: 10.1001/jamadermatol.2017.1547. JAMA Dermatol. 2017. PMID: 28593303 Free PMC article.
-
Melanoma Skin Self-Examination Education During Mammography: Health Burden of Women Impairs Implementation.J Cancer Educ. 2021 Aug;36(4):858-864. doi: 10.1007/s13187-020-01714-4. J Cancer Educ. 2021. PMID: 32090289 Free PMC article.
-
Monitoring patients with multiple nevi.Dermatol Clin. 2013 Oct;31(4):565-77, viii. doi: 10.1016/j.det.2013.06.004. Dermatol Clin. 2013. PMID: 24075545 Review.
Cited by
-
The Imitation Game: Melanoma Metastasis Poses as a Primary Breast Tumor.J Investig Med High Impact Case Rep. 2025 Jan-Dec;13:23247096251345394. doi: 10.1177/23247096251345394. Epub 2025 May 31. J Investig Med High Impact Case Rep. 2025. PMID: 40448522 Free PMC article.
References
-
- Zhang W, Zeng W, Jiang A, He Z, Shen X, Dong X, et al. Global, regional and national incidence, mortality and disability-adjusted life-years of skin cancers and trend analysis from 1990 to 2019: an analysis of the Global Burden of Disease Study 2019. Cancer Med 2021; 10: 4905–4922. 10.1002/cam4.4046 - DOI - PMC - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical